Table 9. References for studies on cisplatin–based chemoradiotherapy regimen (continued).
| CIS-CRT | Study | Severe acute toxicity (grade 3–5) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Arms | Pts (no.) | N/V | Mucositis | Dysphagia | Leukopenia | Neutropenia | Tbcp | Anemia | Infection | Renal | Neuro | Skin | Oto–toxic | Total toxic deaths | All | Diff in acute toxicity | ||
| HDC vs. RT | Pignon et al. (1) | CRT vs. LRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | Not assessed | |
| ICT vs. LRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||||
| Adelstein et al. (2) | A. RT alone | 98 | 6% | 33% | 1% | – | 0 | 0 | – | 1% | – | 13% | – | 2 | 52% | B>A, P<0.0001 | |||
| B. CRT | 95 | 16% | 45% | 42% | – | 3% | 18% | – | 8% | – | 7% | – | 4 | 89% | B>C, P=0.02 | ||||
| C. Split CRT | 94 | 9% | 47% | 31% | – | 3% | 19% | – | 0 | – | 2% | – | 2 | 77% | C>A, P<0.001 | ||||
| Cooper et al. (5) | A. RT alone | 210 | 0 | 18% | 15% | 0 | 0 | 0 | 0 | 0 | 10% | – | 0 | 34% | B>A, P<0.001 | ||||
| B. CRT | 206 | 19% | 30% | 24% | 38% (hematologic) | 3% | 6% | 2% | 5% | 7% | – | 4 | 77% | ||||||
| Bernier et al. (6) | A. RT alone | 167 | – | 21% | 12% | – | – | – | – | – | – | – | 1% | – | 1 | – | B>A, P=001 | ||
| B. CRT | 167 | 12% | 41% | 10% | 16% | 13% | – | – | – | – | – | 2% | – | 1 | – | ||||
| LDC vs. RT | Bachaud et al. (9) | A. RT alone | 44 | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 18% | None reported | |
| B. CRT | 39 | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 41% | ||||
| Sharma et al. (10) | A. RT alone | 76 | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 20% | B>A, P=0.015 | ||
| B. CRT | 77 | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 40% | ||||
| Ghosh-Laskar et al. (11) |
A. RT alone | 57 | – | 21% | – | – | – | – | – | – | – | – | 26% | – | 0 | – | None reported | ||
| B. CRT | 65 | – | 35% | – | – | – | – | – | – | – | – | 23% | – | 2 | – | ||||
| HDC vs. LDC | Lee et al. (12) | A. HDC-CRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| B. LDC-CRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |||
| Helfenstein et al. (13) | A. HDC-CRT | 127 | – | – | – | – | – | – | – | – | 33% | – | – | – | – | – | A>B, P=0.02 | ||
| B. LDC-CRT | 187 | – | – | – | – | – | – | – | – | 21% | – | – | – | – | – | ||||
| Bauml et al. (14) | A. HDC-CRT | 2200 | HDC: higher rate of AKI (HR 1.72, P<0.001), neutropenia (HR 2.21, P=0.005), dehydration (HR 1.15, P=0.04), hearing loss (HR 1.34, P=0.004) | ||||||||||||||||
| B. LDC-CRT | 701 | ||||||||||||||||||
| Szturz et al. (15) | A. HDC-CRT | 25,6 studies | 16, 10% | 42, 37% | 26, 20% | 19, 19% | 18, 14% | 4, 2% | 8, 6% | 5, 11% | 5, 3% | 2, 5% | 11, 6% | 3, 2% | 3, 2% | – | Bold = sig diff | ||
| B. LDC-CRT | 14,3 studies | 3, 16% | 25, 51% | 8, 54% | 1, 12% | 5, 9% | 1, 2% | 4, 3% | 8, NA% | 1, 2% | 1, NA% | 14, 12% | NA, 2% | 2, 1% | – | ||||
| Tsan et al. (16) | A. HDC-CRT | 26 | 12% | 39% | 54% | 0 | 0 | 0 | 4% | – | – | 8% | – | – | 81% | B>A, P=0.02 | |||
| B. LDC-CRT | 24 | 21% | 75% | 54% | 13% | 4% | 0 | 4% | – | – | – | 8% | – | – | 92% | ||||
| Noronha et al. (17) | A. HDC-CRT | 149 | 7% | 18% | 39% | 16% | 13% | 2% | 5% | 34% | 0% | 0% | 8% | 13% | 10 | 85% | A>B, P=0.006 | ||
| B. LDC-CRT | 148 | 1% | 17% | 42% | 3% | 1% | 3% | 2% | 21% | 0% | 0% | 7% | 5% | 5 | 72% | ||||
Cis, cisplatin; CRT, chemoradiation; Pts, patients; N/V, nausea or vomiting; Tbcp, thrombocytopenia; Neuro, neurological; Diff, difference; HDC, high dose cisplatin (80–100 mg/m2 3-weekly, 2–3 cycles); LDC, low dose cisplatin (30–50 mg/m2 weekly, 6–9 cycles); RT, radiotherapy; LRT, locoregional treatment; AKI, acute kidney injury; HR, hazard ratio.